Get access

Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes

Authors

  • Y. S. Davidson,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    Search for more papers by this author
  • A. C. Robinson,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    Search for more papers by this author
  • Q. Hu,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    Search for more papers by this author
  • M. Mishra,

    1. Northwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments of
    Search for more papers by this author
  • A. Baborie,

    1. Department of Neuropathology, Walton Centre for Neurology and Neurosurgery, Liverpool
    Search for more papers by this author
  • E. Jaros,

    1. Neuropathology/Cellular Pathology, Royal Victoria Infirmary
    2. Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
    Search for more papers by this author
  • R. H. Perry,

    1. Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
    Search for more papers by this author
  • N. J. Cairns,

    1. Neurology
    2. Pathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA
    Search for more papers by this author
  • A. Richardson,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    2. Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, Salford
    Search for more papers by this author
  • A. Gerhard,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    2. Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, Salford
    Search for more papers by this author
  • D. Neary,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    2. Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, Salford
    Search for more papers by this author
  • J. S. Snowden,

    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    2. Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, Salford
    Search for more papers by this author
  • E. H. Bigio,

    1. Northwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments of
    Search for more papers by this author
  • D. M. A. Mann

    Corresponding author
    1. Mental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester
    2. Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, Salford
      Prof. David M. A. Mann, Mental Health and Neurodegeneration Research Group, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation NHS Trust, Salford M6 8HD, UK. Tel: +44 (0) 161 206 2580; Fax: +44 (0) 161 206 0388; E-mail: david.mann@manchester.ac.uk
    Search for more papers by this author

Prof. David M. A. Mann, Mental Health and Neurodegeneration Research Group, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation NHS Trust, Salford M6 8HD, UK. Tel: +44 (0) 161 206 2580; Fax: +44 (0) 161 206 0388; E-mail: david.mann@manchester.ac.uk

Abstract

Y. S. Davidson, A. C. Robinson, Q. Hu, M. Mishra, A. Baborie, E. Jaros, R. H. Perry, N. J. Cairns, A. Richardson, A. Gerhard, D. Neary, J. S. Snowden, E. H. Bigio and D. M. A. Mann (2013) Neuropathology and Applied Neurobiology39, 157–165

Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes

Aims: We aimed to investigate the role of the nuclear carrier and binding proteins, transportin 1 (TRN1) and transportin 2 (TRN2), TATA-binding protein-associated factor 15 (TAF15) and Ewing's sarcoma protein (EWS) in inclusion body formation in cases of frontotemporal lobar degeneration (FTLD) associated with fused in sarcoma protein (FTLD-FUS). Methods: Eight cases of FTLD-FUS (five cases of atypical FTLD-U, two of neuronal intermediate filament inclusion body disease and one of basophilic inclusion body disease) were immunostained for FUS, TRN1, TRN2, TAF15 and EWS. Ten cases of FTLD associated with TDP-43 inclusions served as reference cases. Results: The inclusion bodies in FTLD-FUS contained TRN1 and TAF15 and, to a lesser extent, EWS, but not TRN2. The patterns of immunostaining for TRN1 and TAF15 were very similar to that of FUS. None of these proteins was associated with tau or TDP-43 aggregations in FTLD. Conclusions: Data suggest that FUS, TRN1 and TAF15 may participate in a functional pathway in an interdependent way, and imply that the function of TDP-43 may not necessarily be in parallel with, or complementary to, that of FUS, despite each protein sharing many similar structural elements.

Get access to the full text of this article

Ancillary